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Head and neck squamous cell carcinomaHigh-risk human papillomaviruses (HPVs) contribute to cervical and other anogenital cancers, and they are
also linked etiologically to a subset of head and neck squamous cell carcinomas (HNSCC). We previously
established a model for HPV-associated HNSCC in which we treated transgenic mice expressing the
papillomaviral oncoproteins with the chemical carcinogen 4-nitroquinoline-1-oxide (4-NQO). We found that
the HPV-16 E7 oncoprotein was highly potent in causing HNSCC, and its dominance masked any potential
oncogenic contribution of E6, a second papillomaviral oncoprotein commonly expressed in human cancers.
In the current study, we shortened the duration of treatment with 4-NQO to reduce the incidence of cancers
and discovered a striking synergy between E6 and E7 in causing HNSCC. Comparing the oncogenic properties
of wild-type versus mutant E6 genes in this model for HNSCC uncovered a role for some but not other
cellular targets of E6 previously shown to contribute to cervical cancer.ent of Biological Sciences,
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
High-risk human papillomaviruses (HPVs) are causative agents of
nearly all cervical cancers and more recently have been implicated in
the development of a subset of cancers of the head and neck.
Approximately one ﬁfth of all head and neck squamous cell
carcinomas (HNSCCs) contain HPV DNA, and the vast majority of
HPV-positive HNSCCs harbor HPV-16 DNA in particular (Gillison,
2004). The papillomaviral E6 and E7 oncoproteins can bind to and
stimulate the degradation of the tumor suppressors p53 (Huibregtse
et al., 1991; Scheffner et al., 1993, 1990;Werness et al., 1990) and pRb
(Boyer et al., 1996; Dyson et al., 1989), respectively, and although
their oncogenic potentials are largely correlated with these interac-
tions (Heck et al., 1992; Nguyen et al., 2002), their interference with
the functions of other intracellular proteins likely plays important
roles as well (Balsitis et al., 2006, 2005; Shai et al., 2007b; Song et al.,
1998). The expression of E6 and E7 in HPV-positive HNSCC is
correlated with an intact TP53 gene, reduced expression of pRb, and
elevated levels of p16; in contrast, HPV-negative HNSCC generally
retains an intact TP53 gene, displays normal expression of pRb, and
displays an up-regulation of p16 (Balz et al., 2003; Hafkamp et al.,
2003; Wiest et al., 2002). Furthermore, the expression of E6 and E7 is
required for the maintenance of the transformed phenotype of celllines derived from HPV-positive oropharyngeal cancers (Rampias et
al., 2009). HPV-positive HNSCC often has a more basaloid morphology
when compared with HPV-negative disease (Gillison et al., 2000) and
individuals with HPV-positive HNSCC tend to be younger and less
likely to be regular users of tobacco and alcohol than people with
HPV-negative HNSCC (Lindel et al., 2001). In sum, these data suggest
that HPVs in general and both viral oncogenes in particular play a
causal role in the genesis of a subset of oropharyngeal cancers.
K14E6 (Song et al., 1999) and K14E7 (Herber et al., 1996) transgenic
mice, in which expression of the individual HPV16 oncogenes are
directed to the stratiﬁed squamous epithelium by the human keratin
14 (K14) promoter, were previously generated and characterized. In
the murine cervix, HPV-16 E6 (Shai et al., 2007a) and E7 (Riley et al.,
2003) each was found to be capable of cooperating with exogenous
estrogen to induce cervical cancers, although E6 expressing mice
required a longer period of treatment with exogenous estrogen to give
rise to cancers. Additionally, the two oncogenes, when expressed
together, led to increases in the incidence and size of cervical
carcinomas compared to mice expressing either one oncogene (Brake
and Lambert, 2005; Riley et al., 2003). In the head and neck, E7 was
likewise found to be the dominant oncogene, synergizing with the
chemical carcinogen4-nitroquinoline-1-oxide (4-NQO) to inducehead
and neck cancers in mice. In contrast, like-treated E6 transgenic mice
failed to develop HNSCC (Strati and Lambert, 2007). Consistent with
the dominant oncogenic properties of E7 in the head and neck region,
there was no signiﬁcant difference in the severity or incidence of
neoplastic disease arising in K14E7 transgenic versus K14E6/K14E7 bi-
transgenic mice under the condition used in these prior studies (Strati
and Lambert, 2007; Strati et al., 2006).
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its interference with the tumor suppressive role of p53 is by far its
best-studied activity. E6 and the intracellular ubiquitin ligase E6-
associated protein (E6-AP) can bind to p53 in a ternary complex and
induce its proteasomal degradation (Huibregtse et al., 1991; Scheffner
et al., 1993, 1990; Werness et al., 1990); however, whether this is the
only mechanism by which E6 can cause the degradation of p53
currently is unclear (Massimi et al., 2008; Shai et al., 2007b). E6-AP
binds to E6 using a conservedα-helical motif (Chen et al., 1998; Elston
et al., 1998) which is shared by a variety of other binding partners of
E6, including E6-binding protein (E6-BP) (Chen et al., 1995; Elston et
al., 1998), paxillin (Chen et al., 1998; Vande Pol et al., 1998), tuberin
(Elston et al., 1998; Lu et al., 2004), and interferon regulatory factor-3
(IRF-3) (Ronco et al., 1998). In addition to α-helical binding partners,
E6 also can bind to several members of the post-synaptic density
protein 95/Drosophila Discs large/zonula occludens-1 (PDZ)-domain
family, which includes the Scribble (Scrib) (Massimi et al., 2008;
Nakagawa and Huibregtse, 2000) and Discs large (Dlg) (Gardiol et al.,
1999; Kiyono et al., 1997) proteins; notably, both proteins are tumor
suppressors in Drosophila (Bilder et al., 2000; Gateff, 1978; Murphy,
1974; Stewart et al., 1972). Lastly, E6 can interact with a host of other
proteins involved in the regulation of apoptosis, genomic stability,
epithelial differentiation, and transcription, many of which bind
through alternative or unknown motifs (reviewed in (Tungteakhum
and Duerksen-Hughes, 2008).
To determinewhich families of binding partners of E6 are important
in mediating its oncogenicity, we previously generated and used
K14E6I128T (Nguyen et al., 2002) and K14E6Δ146–151 (Nguyen et al.,
2003a,b) transgenicmice,which expressmutant formsof the E6protein
deﬁcient in binding to α-helical (Liu et al., 1999) and PDZ-domain
binding partners, respectively. K14E6I128T mice do not develop as many
spontaneous epidermal carcinomas as K14E6mice, nor do they develop
as many epidermal papillomas and carcinomas as K14E6 mice in
cooperation with topical treatment with initiating and promoting
agents (Nguyen et al., 2002). In addition, studying K14E6I128T mice
treated chronically with estrogen revealed that the interaction of E6
withα-helical binding partners contributes to the incidence and size of
cervical cancers (Shai et al., 2007a). K14E6Δ146–151 mice do not develop
signiﬁcantly more spontaneous epidermal tumors than non-transgenic
mice and display defects in the promotion of the development of
papillomas in cooperation with topical treatment with chemical agents
(Simonson et al., 2005). Unlike inK14E6I128Tmice, however, deﬁciencies
in the ability of E6Δ146–151 to contribute to cervical carcinogenesis
appear only in the context of the co-expression of E7 (Shai et al., 2007a).
These data indicate that both α-helical and PDZ-domain binding
partners of E6 contribute to the genesis of neoplastic disease in the
skin and in the cervix.
The aim of the study described herein was to assess the
contribution of E6 to HNSCC. In our previous studies assessing the
roles of HPV-16 E6 and E7, we treated transgenic mice with the
chemical carcinogen 4-NQO in their drinking water for 16 weeks and
then maintained them for an additional 8 weeks in the absence of the
drug. Under those conditions, wewere unable to discern an individual
contribution of HPV-16 E6 or its possible synergy with HPV-16 E7 in
HNSCC, possibly due to the combined oncogenic potencies of both E7
and 4-NQO. Therefore, we halved the duration of exposure to 4-NQO
from 16 weeks to 8 weeks, and we found that, although neither K14E6
nor K14E7 mice developed signiﬁcantly more head and neck tumors
compared to non-transgenic mice, similarly treated K14E6/K14E7
mice expressing both HPV-16 E6 and E7 developed a signiﬁcantly
higher incidence of HNSCC. Therefore, E6 can contribute to HNSCC,
and it does so by synergizing with E7. By studying K14E6I128T/K14E7
and K14E6Δ146–151/K14E7mice treated with 4-NQO, we found that the
ability of E6 to synergizewith E7 in causing head and neck cancer does
not correlate with its ability to interact with its PDZ-domain binding
partners and only partially correlates with its ability to interact withα-helical partners. We conclude that the ability of E6 to synergize
with E7 in contributing to HNSCC likely involves its interactions with
multiple families of its binding partners.
Results
HPV16 E6 is functionally expressed in head/neck epithelia in K14E6
transgenic mice
In K14E6 mice, the HPV16 E6 oncoprotein is directed in its
expression from the human keratin 14 (K14) promoter, which should
direct expression of E6 to all stratiﬁed squamous epithelia, including
in head/neck tissues. Our prior studies with K14E7 mice clearly
showed that HPV16 E7, when expressed from the same K14 promoter
was expressed and functional as an oncoprotein in head/neck
epithelia. In the current study in which we evaluated the role of E6
in HNSCC using K14E6 mice, we wanted to establish that E6 is
expressed and functional in the head and neck epithelia. Speciﬁcally
we asked whether in K14E6 mice HPV16 E6 can inactivate p53 in the
epithelia of the tongue and esophagus. A functional readout for E6's
inactivation of p53 in vivo is its ability to abrogate normal DNA
damage responses. We therefore irradiated nontransgenic and K14E6
transgenic mice with 12 Gy ionizing radiation, a dose sufﬁcient to
elicit growth arrest in the epithelium of the tongue and esophagus.
24 h post irradiation, we scored for cell proliferation by counting the
number of cells labeledwith BrdU 1 h prior to harvesting the tissue. As
expected, the epithelia of the tongue (Fig. 1A) and esophagus (Fig. 1B)
in nontransgenic mice underwent growth arrest, as evidenced by a
reduction in the frequency of BrdU-positive cells. In contrast, K14E6
mice were completely abrogated in this response in both the tongue
(Fig. 1A) and esophagus (Fig. 1B); no decrease in the frequency of
BrdU-positive cells was observed in the irradiated K14E6 mice. These
data demonstrate that HPV16 E6 is expressed and functional in head/
neck epithelia in K14E6 mice.
We further wanted to conﬁrm the properties of the mutant E6
proteins in the head and neck tissues of K14E6I128T and K14E6Δ146–151
transgenic mice, as these transgenic mice were used in this study to
investigate the mechanism of action of E6 in HNSCC. E6I128T is
predicted to be unable to inactivate p53; whereas E6Δ146–151 is known
to retain this activity. Consistent with prior results in the skin of these
transgenic mice, we observed that K14E6I128T mice were not
abrogated in their response to ionizing radiation in the tongue
(Fig. 1A) and esophagus (Fig. 1B); whereas K14E6Δ146–151 mice were
abrogated in their response in these same tissues (Fig. 1A and B).
HPV-16 E6 can contribute to HNSCC by synergizing with E7
Our laboratory previously investigated the roles of the papilloma-
viral oncogenes in HNSCC by treating adult K14E6, K14E7, and K14E6/
K14E7 mice with 4-NQO for the ﬁrst 16 weeks of a 24-week
experimental period (Strati and Lambert, 2007; Strati et al., 2006).
Under this regimen of treatment, K14E6 mice did not display a
signiﬁcant increase in the incidence of head and neck tumors (23%)
over that observed in similarly treated non-transgenic mice (16%). On
the other hand, similarly treated K14E7 and K14E6/K14E7 mice
developed tumors at high incidences (96% and 95%, respectively;
pb10−6 for both versus non-transgenic mice, two-sided Fisher's exact
tests). Based on these results, we concluded that E7 is the dominant
papillomaviral oncogene in the head and neck, and its dominance
masked any potential contribution of E6 to HNSCC.
To try to reveal a contribution of E6 to HNSCC, we halved the
duration of treatment with 4-NQO from 16 weeks to 8 weeks and
subsequently held themice in the absence of 4-NQO for the remainder
of the aforementioned 24-week period. As with the previously used
16-week treatment with 4-NQO (Strati and Lambert, 2007), the 8-
week treatment did not lead to a signiﬁcant increase in the severity of
Fig. 1. Response of head and neck epithelia to ionizing radiation. Shown in panels A and
B are the percentage BrdU-positive cells present in tongue and esophagus epithelia,
respectively, from mice that were (black bars) or were not (white bars) exposed to
12 Gy ionizing radiation (see Materials and methods for complete description of
protocol used). For each condition and genotype, three mice were evaluated. In both
tissues, signiﬁcant reductions (pb0.05 based upon 2-sided Wilcoxon rank sum test) in
Brdu-positive cells were observed only in the nontransgenic and the K14E6I128T
transgenic mice (see *). In contrast there was the complete abrogation of growth arrest
in the K14E6 and K14E6Δ146–151 mice, consistent with inactivation of p53.
Table 2
Incidence of tumors and carcinomas in the head and neck.
Genotype nb Incidence of:a Average
multiplicity
of tumorsc
Tumors
(%)
Carcinomas
(%)
Multiple
tumors (%)
Non-transgenic 34 2 (5.9) 2 (5.9) − (−) 0.059
K14E6 20 2 (10) 1 (5) − (−) 0.10
K14E7 22 5 (23) 1 (4.6) 1 (4.6) 0.27
K14E6/K14E7 26 18 (69)d,e 12 (46)d,e 8 (31)d,e 1.0f,g
K14E6I128T/K14E7 29 15 (52)d,e,j 13 (45)d,e,k 2 (6.9)h 0.59f,g,i
K14E6Δ146–151/K14E7 27 14 (52)d,e,j 9 (33)d,e,k 6 (22)d 0.75f,g
a The number of mice of each genotype with tumors, cancers, or multiple tumors is
listed, with the percentage indicated in parentheses.
b Total number of mice examined for each genotype.
c Total number of tumors divided by the total number of mice (n) for each genotype.
d pb0.008 vs. non-transgenic mice, two-sided Fisher's exact test.
e pb0.05 vs. K14E7 mice, two-sided Fisher's exact test.
f pb10−4 vs. non-transgenic mice, two-sided Wilcoxon rank-sum test.
g pb0.05 vs. K14E7 mice, two-sided Wilcoxon rank-sum test.
h pb0.03 vs. K14E6/K14E7 mice, two-sided Fisher's exact test.
i pb0.05 vs. K14E6/K14E7 mice, two-sided Wilcoxon rank-sum test.
j pN0.25 vs. K14E6/K14E7 mice, two-sided Fisher's exact test.
k pN0.40 vs. K14E6/K14E7 mice, two-sided Fisher's exact test.
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or multiple tumors (Table 2); the multiplicity of tumors (Table 2); or
the per-mouse average size of tumors (Fig. 2) in K14E6 mice when
compared to non-transgenic mice.Table 1
Summary of overt disease in the head and neck.
Genotype nb No
tumors
Histological grade of tumora
Papilloma Carcinoma
I II III IV
NTG 34 32 – 1 1 – –
K14E6 20 18 1 1 – – –
K14E7 22 17 4 1 – – –
K14E6/K14E7c,d 26 8 6 7 4 – 1
K14E6I128T/K14E7c,d,e 29 14 2 10 3 – –
K14E6Δ146–151/K14E7c,d,e 27 13 5 6 1 2 –
a Overt tumors were harvested and scored histopathologically as papillomas or
graded (I–IV) as carcinomas, and mice then were assigned a diagnosis based on the
most severe lesion observed. The number of mice assigned into each category is
indicated.
b Total number of mice examined for each genotype.
c pb0.001 vs. non-transgenic mice, two-sided Wilcoxon rank-sum test.
d pb0.02 vs. K14E7 mice, two-sided Wilcoxon rank-sum test.
e pN0.21 vs. K14E6/K14E7 mice, two-sided Wilcoxon rank-sum test.When we examined K14E7 mice treated with 4-NQO for 8 weeks,
we observed a sharp reduction in the oncogenic phenotypes
previously observed when they were treated for 16 weeks (Strati
and Lambert, 2007). Compared with non-transgenic mice, we
observed only marginal increases in K14E7 mice in the severity of
head and neck neoplastic disease (p≈0.087, two-sided Wilcoxon
rank-sum test; Table 1), the incidence of tumors (23% versus 5.9%, p≈
0.099, two-sided Fisher's exact test; Table 2), the multiplicity of
tumors (0.27 versus 0.059, p≈ 0.061, two-sided Wilcoxon rank-sum
test; Table 2), and the average total size of tumors per mouse
(0.59 mm versus 0.18 mm, p≈ 0.075, two-sided Wilcoxon rank-sum
test; Fig. 2). Furthermore, K14E7 mice treated for 8 weeks did not
display an increase in the incidence of cancer or of multiple tumors
over that observed in non-transgenic mice treated similarly (Table 2).
Therefore, shortening the 16-week treatment with 4-NQO to 8 weeks
strongly reduces the ability of E7 alone to induce head and neck
tumors.
Our interest then turned to the incidence and severity of neoplastic
disease in K14E6/K14E7 bi-transgenic mice. In stark contrast to what
we observed in K14E6 and K14E7 singly transgenic mice, halving the
duration of treatment of bi-transgenic mice with 4-NQO still led to a
signiﬁcant increase over what was seen in non-transgenic mice with
regard to the severity of histopathological disease (pb10−5, two-
sided Wilcoxon rank-sum test; Table 1); the incidences of tumors,
cancers, and multiple tumors (69% versus 5.9%, pb10−6; 46% versus
5.9%, pb10−3; and 31% versus 0%, pb10−3; respectively, two-sided
Fisher's exact tests; Table 2); the multiplicity of tumors (1.0 versus
0.059, pb10−6, two-sided Wilcoxon rank-sum test; Table 2); and the
average size of tumors per mouse (3.1 mm versus 0.18 mm, pb0.003,
two-sided Wilcoxon rank-sum test; Fig. 2). Moreover, all of these
measures of disease were increased in K14E6/K14E7 mice compared
with K14E7 mice (pb0.05, two-sided Wilcoxon rank-sum or Fisher's
exact tests; Tables 1 and 2; Fig. 2). These comparisons demonstrate
that after the 8-week treatmentwith 4-NQO, E6 can synergize with E7
to drive the development of HNSCC.
Eliminating the interaction between E6 and its PDZ-domain binding
partners does not affect its ability to synergize with E7 in HNSCC
We next investigated which of the families of binding partners of
E6 were contributing to its ability to synergize with E7 to drive
HNSCC. To do this, we used two previously generated lines of
transgenic mice that harbor mutant versions of the HPV-16 E6 gene.
K14E6Δ146–151 transgenic mice express a truncated form of E6
Fig. 2. Total size per mouse of head and neck tumors in mice treated with 4-NQO. Each dot represents the cumulative measured size of tumors in onemouse. The average total size of
tumors per mouse is listed in parentheses under the genotypes. ⁎pb10−4 versus non-transgenic mice and †pb0.03 versus K14E7 mice, two-sided Wilcoxon rank-sum tests. There
were no signiﬁcant differences between K14E6mutant/K14E7 and K14E6/K14E7 mice (pN0.20, two-sided Wilcoxon rank-sum tests).
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domains (Nguyen et al., 2003a), such as Dlg (Gardiol et al., 1999;
Kiyono et al., 1997) and Scrib (Massimi et al., 2008; Nakagawa and
Huibregtse, 2000), both of which are considered to be tumor
suppressors in Drosophila (Bilder et al., 2000). K14E6I128T transgenic
mice express an E6 protein that has a severely reduced ability to bind
to theα-helical partners (Nguyen et al., 2002), including E6-AP (Liu et
al., 1999); notably, a ternary complex of E6 and E6-AP can interact
with and induce the degradation of p53 (Huibregtse et al., 1991;
Scheffner et al., 1993, 1990; Werness et al., 1990). By comparing the
severity, incidence, and multiplicity of disease between K14E6/K14E7
and these K14E6mutant/K14E7 mice, we were able to determine
whether the α-helical or PDZ-domain binding partners of E6 are
important in contributing to its synergistic role in HNSCC.
We ﬁrst compared K14E6Δ146–151/K14E7 mice to K14E6/K14E7
mice to assess whether there were defects in the ability of E6Δ146–151
to synergize oncogenically with E7 compared with wild-type E6. We
found no difference in the severity of disease between the two cohorts
treated for 8 weeks with 4-NQO (Table 1). In addition, the incidences
of tumors, cancers, and multiple tumors, as well as the multiplicity of
tumors, were statistically indistinguishable between the two groups
of mice (Table 2). Lastly, the per-mouse average size of tumors in
K14E6/K14E7 and K14E6Δ146–151/K14E7 mice was not signiﬁcantly
different (Fig. 2). The similarities between the phenotypes observed in
K14E6Δ146–151/K14E7 mice and K14E6/K14E7 mice suggest that the
interactions between E6 and its PDZ-domain binding partners are not
critical for its synergywith E7 in inducing head and neck cancer in this
model.We also compared K14E6Δ146–151/K14E7 mice to K14E7 mice to
determine whether E6Δ146–151 still was capable of increasing the
severity or incidence of disease observed in the presence of E7 alone.
The severity of disease (pb0.02, two-sided Wilcoxon rank-sum test;
Table 1), incidences of tumors and cancers (52% versus 23%, pb0.05 and
33% versus 4.6%, pb0.02, respectively, two-sided Fisher's exact test;
Table 2), multiplicity of tumors (0.75 versus 0.27, pb0.03, two-sided
Wilcoxon rank-sum test; Table 2), and average total size of tumors per
mouse (4.3 mm versus 0.59 mm, pb0.008, two-sided Wilcoxon rank-
sum test; Fig. 2) were increased in K14E6Δ146–151/K14E7 mice when
comparedwithK14E7mice, indicating that E6Δ146–151 still can synergize
with E7 to increase most of the parameters of head and neck neoplastic
disease. Interestingly, however, the incidence of multiple tumors in
K14E6Δ146–151/K14E7 mice was only marginally increased when
compared to K14E7mice (22% versus 4.6%, p≈0.11, two-sided Fisher's
exact test; Table 2), indicating that K14E6Δ146–151 may have very subtle
defects in its oncogenic potential when compared with wild-type E6.
Overall, though, these data indicate that E6Δ146–151 still can synergize
with E7 to contribute to HNSCC.
Strongly reducing the interaction of E6 with its α-helical binding
partners reduces its ability to synergize with E7 in HNSCC
In order to determine the importance of the interaction of E6 with
α-helical binding partners in its ability to synergize with E7, we next
examined the oral cavities and esophagi of K14E6I128T/K14E7 mice
treated with 4-NQO for 8 weeks and compared them with those of
similarly treated K14E6/K14E7 mice. As with K14E6Δ146–151/K14E7
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pared to K14E6/K14E7 mice with respect to the severity of disease
(Table 1), the incidence of tumors or cancers (Table 2), or the per-
mouse average size of tumors (Fig. 2). However, we noted a signiﬁcant
reduction in the incidence of multiple tumors (6.9% versus 31%,
pb0.04, two-sided Fisher's exact test; Table 2) and the multiplicity of
tumors (0.59 versus 1.0, pb0.05, two-sided Wilcoxon rank-sum test;
Table 2) in K14E6I128T/K14E7 versus K14E6/K14E7 mice, suggesting
that the interaction of E6 with α-helical binding partners contributes
subtly to its ability to synergize with E7.
When we compared K14E6I128T/K14E7 mice to K14E7 mice, we
found that E6I128T still was able to increase the severity of disease
(pb0.01, two-sided Wilcoxon rank-sum test; Table 1), the incidences
of tumors and cancers (52% versus 23%, pb0.05 and 45% versus 4.6%,
pb0.002, respectively, two-sided Fisher's exact tests; Table 2), and the
average total size of tumors per mouse (2.1 mm versus 0.59 mm,
pb0.03, two-sided Wilcoxon rank-sum test; Fig. 2) over what we
observed in K14E7 singly transgenic mice. The incidence of multiple
tumors in K14E6I128T/K14E7 mice, however, was not signiﬁcantly
altered compared to K14E7 mice (Table 2). Lastly, even though the
average multiplicity of tumors in K14E6I128T/K14E7mice was reduced
compared to K14E6/K14E7 mice, it was still higher than what was
observed in K14E7 mice (0.59 versus 0.27, pb0.05, two-sided
Wilcoxon rank-sum test; Table 2). Thus, interfering with the binding
of E6 to its α-helical partners strongly reduces its ability to synergize
with E7 to induce multiple head and neck tumors; however, E6I128T
still can contribute subtly in combination with E7 to increase the
multiplicity of tumors. Overall, E6I128T is partially defective in its
ability to synergize with E7 in the development HNSCC.
Discussion
Using our mouse model, we unmasked the contribution of HPV-16
E6 to HNSCC and found that it can synergize with E7 to drive the
development of head and neck tumors. We used transgenic mice
encoding mutated versions of E6 to show that its interactions with
PDZ-domain binding partners are not critical for this synergy,
whereas its interactions with α-helical partners partially contribute
to it. Our data indicate that the mechanisms by which E6 synergizes
with E7 in the head and neck differ from those observed in the cervix,
where the interactions of E6 with both PDZ-domain and α-helical
binding partners contribute to the growth of cervical cancer (Shai et
al., 2007a).
HPV-16 E6 can synergize with E7 to contribute to the development of
HNSCC
Previously in the head and neck, we were unable to determine
whether the expression of E6 is important to carcinogenesis because
the 16-week treatment with 4-NQO that we had used led to similar
incidences of tumors, cancers, and multiple cancers in K14E7 and
K14E6/K14E7 mice (Strati and Lambert, 2007). By reducing the
duration of treatment with 4-NQO from 16 weeks to 8 weeks, we
were able to reduce the severity of disease and incidences of tumors
and cancers in K14E7mice sufﬁciently to reveal signiﬁcant differences
in several parameters of neoplastic head and neck disease when we
compared them to similarly treated K14E6/K14E7 mice (Tables 1 and
2; Fig. 2). Therefore, E6 can synergize with E7 to drive the genesis of
head and neck tumors, although based on these and previous (Strati
and Lambert, 2007) results it is a weaker oncogene in the head and
neck than E7.
In the murine cervix, as in the head and neck, E7 is a more potent
oncogene than E6, as K14E7 mice develop cervical cancers within
6 months of chronic treatment with estrogen (Riley et al., 2003)
whereas K14E6mice require 9 months of continuous treatment (Shai
et al., 2007a). In the skin, a small proportion of K14E6 mice developspontaneous carcinomas late in life, but K14E7 mice develop only
benign papillomas; furthermore, E6 but not E7 can induce the
progression of chemically induced epidermal papillomas to carcino-
mas, indicating that E6 is the more potent of the two oncogenes in the
skin (Song et al., 2000). The reasons that E6 is more oncogenically
potent in the epidermis than at mucosal sites are not understood, but
they may involve the differential expression of target proteins of the
viral oncogenes in different tissues or a differential importance of the
pathways with which the oncogenes interfere in controlling prolif-
eration in different types of stratiﬁed squamous epithelia.
Binding to PDZ-domain partners is not critical to the ability of E6 to
synergize with E7 in HNSCC
The incidence of multiple tumors in K14E6Δ146–151/K14E7 (22%)
was intermediate between that of K14E7 (4.6%) and K14E6/K14E7
(31%) mice (Table 2). Therefore, E6Δ146–151 does have a subtle defect
in contributing to the growth of multiple head and neck tumors when
compared with wild-type E6, but the defect was not strong enough to
lead to a statistically signiﬁcant reduction in the incidence of multiple
tumors in K14E6Δ146–151/K14E7mice compared to K14E6/K14E7mice.
In the context of other parameters of tumorigenicity, there was
effectively no difference in the ability of E6Δ146–151 versus wild-type
E6 to synergize with E7 (Tables 1 and 2; Fig. 2).
We were surprised to see so little an effect of eliminating the
interaction of E6 with its PDZ-domain binding partners, because the
PDZ-binding motif is found exclusively in the E6 proteins of high-risk
HPVs and therefore is thought to be critical to their ability to cause
cancers. Two PDZ-domain binding partners of E6, Dlg and Scrib, are
tumor suppressors in Drosophila (Bilder et al., 2000; Gateff, 1978;
Murphy, 1974; Stewart et al., 1972), and these and many other
members of the PDZ-domain family targeted by E6 regulate several
processes important to malignancy, including cellular polarity,
adhesion, and proliferation (reviewed in (Thomas et al., 2008)).
Although the E6 protein of rhesus papillomavirus type 1 (RhPV-1),
which is the only other type of papillomavirus besides HPV that is a
causative agent of cervical cancers in its host, lacks a PDZ-binding
motif, the RhPV-1 E7 protein contains one (Tomaic et al., 2009).
Furthermore, K14E6Δ146–151 mice display obvious defects in the
growth of spontaneous and chemically induced epidermal papillomas
when compared with K14E6 mice (Simonson et al., 2005), and
K14E6Δ146–151/K14E7 mice develop fewer and smaller cervical
carcinomas than K14E6/K14E7 mice when treated chronically with
estrogen (Shai et al., 2007a), showing that the PDZ-binding motif of
E6 is important for its oncogenicity in the skin and cervix. While our
study is the ﬁrst to examine the role of the interaction between E6 and
the PDZ-domain proteins in head and neck neoplasia in vivo, it was
shown recently that E6Δ146–151 is defective in promoting the
anchorage-independent growth and immortalization of primary
human tonsillar epithelial cells (HTECs) (Spanos et al., 2008). These
cells are particularly relevant in that tonsillar cancers are predomi-
nantly HPV-positive. Thus, previous studies have suggested an
important oncogenic role for the binding of PDZ-domain proteins by
E6.
There are several possible reasons that may explain why our
results contrast so sharply with previous studies. We have shown
previously that HPV-16 E6 does not induce the degradation of Dlg or
Scrib in the murine epidermis (Simonson et al., unpublished results),
but it does reduce the levels of Scrib in the murine lens (Nguyen et al.,
2003b). It is possible, therefore, that E6 does not induce the
degradation of some or all of the PDZ-domain proteins to which it
binds in murine head and neck epithelial cells. This might allow them
to retain some function even if they are bound by E6, although
degradation is not necessarily the only way in which E6 could
interfere with the functions of its PDZ-domain binding partners. It is
also conceivable that PDZ-domain proteins play less important tumor
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epidermis and cervical epithelium, so their inactivation by E6 may not
be critical to the genesis of head and neck tumors. E6 proteins from
different high-risk types of HPVs have been shown to bind with
different afﬁnities to various PDZ-domain proteins–HPV-18 E6 binds
to Dlg and membrane-associated guanylate kinase with inverted
domain structure (MAGI)-1 more strongly than HPV-16 E6 (Pim et al.,
2000; Thomas et al., 2001), for example–and the proteins boundmost
strongly by HPV-16 E6, which include Scrib (Thomas et al., 2005), may
be the less important for the maintenance of head and neck epithelial
cell polarity and adhesion. In addition, there could be some functional
compensation (Kocher et al., 2003; Misawa et al., 2001) for the loss of
PDZ-domain proteins in the oral cavity by proteins either not bound
or bound only weakly by HPV-16 E6, although it is important to note
that such compensation has not been shown to occur among the PDZ-
domain proteins bound by E6.While the aforementioned experiments
performed in HTECs (Spanos et al., 2008) showed the importance of
the PDZ-domain binding motif of E6 in immortalizing oral keratino-
cytes in tissue culture, they relied on the transduction of HTECs with
HPV-16 E6 and E7 andmay not be predictive of the behavior of cancers
in vivo. Furthermore, it is unlikely that anchorage-independent
growth and immortalization correlate perfectly with malignancy. On
the other hand, our carcinogenesis study was carried out in mice,
which may differ in their sensitivity to PDZ protein function at least in
the head/neck region. Furthermore our mouse model relies upon use
of a chemical carcinogen, 4NQO, which could mask a role of certain
activities of E6. Characterizing the levels of expression of PDZ-domain
proteins in the presence and absence of E6 in the oral epithelium,
investigating the effects on the oral epithelium of the loss of their
individual or combined expression, and comparing results obtained
with HPV-16 E6 with future studies examining the E6 proteins from
other high-risk types of HPVs will be important in addressing further
themechanism of action of E6 in HNSCC. Such experiments could help
to elucidate the reasons behind the surprisingly subtle defects in the
oncogenicity of HPV-16 E6Δ146–151 in the head and neck.
The binding of HPV-16 E6 to α-helical partners weakly contributes to its
ability to synergize with E7 in HNSCC
In contrast to PDZ-domain binding partners of E6, the interaction
with α-helical binding partners by E6 was critical for its ability to
induce multiple tumors with E7 (Table 2). In addition, the average
multiplicity of tumors in K14E6I128T/K14E7mice (0.59 permouse) was
intermediate between the multiplicities observed in K14E7 (0.27) and
K14E6/K14E7 (1.0) transgenic mice (Table 2), indicating that E6I128T
has defects in synergizing with E7 to increase the multiplicity of head
and neck tumors. In contrast, in the cervix, the interactions of E6 with
α-helical partners contribute to the incidence and size of tumors in the
absence of E7 but only to the size of tumors in the presence of E7 (Shai
et al., 2007a). Comparing our results with these previous conclusions
from the study in the cervix suggests that in different tissues, the
binding of E6 to its families of partners may contribute to carcinogen-
esis differently. However, we cannot exclude the possibility that the
two different carcinogens used in this study and in the study
investigating cervical cancer–4-NQO and estrogen, respectively–
differentially affect the importance of the interactions of E6 with its
binding partners to tumorigenesis. Regardless, E6128T was still able to
synergize with E7 in driving most aspects of neoplastic disease in the
head and neck.
The best-studied interaction affected by the E6I128T mutation is the
one between E6 and E6-AP, which together can bind to p53 and
induce its degradation (Huibregtse et al., 1991; Scheffner et al., 1993,
1990; Werness et al., 1990). E6I128T binds to E6-AP and induces the
degradation of p53 with less than 5% the ability of wild-type E6 (Liu et
al., 1999), and its reduced ability to degrade p53 is probably the most
obvious mechanism by which this mutation in E6 could lead to adecrease in the both the incidence of multiple tumors and the
multiplicity of tumors (Table 2). Importantly, E6I128T does retain some
binding to E6-AP (Liu et al., 1999), so it remains possible that residual
degradation of p53 by an E6I128T/E6-AP complex may be sufﬁcient to
synergize with E7 in head and neck tumorigenesis; this may be one
reason that we did not observe a more drastic reduction in neoplastic
phenotypes when comparing K14E6I128T/K14E7mice to K14E6/K14E7
mice. It has been shown previously that knocking out p53 contributes
to both epidermal (Kemp et al., 1993) and cervical (Shai et al., 2008)
carcinogenesis, but in neither tissue is eliminating p53 sufﬁcient to
recapitulate the full oncogenic potential of E6. Because the E6I128T
mutation does not ablate selectively the degradation of p53 (Liu et al.,
1999), further studies involving p53−/−mice or mice in which p53 is
deleted conditionally likely are necessary to assess the importance of
the degradation of p53 to the oncogenicity of E6 in the head and neck.
In addition to E6-AP, E6I128T is also deﬁcient in binding to E6-BP
(Liu et al., 1999), which is a calcium-binding protein that may be
involved in the differentiation of epithelial cells (Chen et al., 1995),
although its role and the effect of its binding to E6 are not understood
(Sherman et al., 2002). Many other proteins–minichromosome
maintenance protein 7 (MCM7) (Kuhne and Banks, 1998; Kukimoto
et al., 1998), a licensing factor for the replication of DNA; IRF-3 (Ronco
et al., 1998), a transcription factor that induces the expression of
interferons; paxillin (Chen et al., 1998; Tong and Howley, 1997),
which is associatedwith focal adhesion proteins and is thought to play
a role in the organization of actin; tuberin (Elston et al., 1998), a
putative tumor suppressor; and transcriptional regulator interacting
with the plant homeodomain–bromodomain 1 (TRIP-Br1) (Gupta et
al., 2003), a transcriptional co-activator and regulator of the cell
cycle–are predicted to associate with E6 using the same α-helical
motif shared by E6-AP and E6-BP. Whether the E6I128T mutant is
defective for binding to any of them has not been investigated
speciﬁcally. Furthermore, several binding partners of E6 other than
p53, including the proto-oncogene N-Myc (Gross-Mesilaty et al.,
1998) and the 91-kDa splice variant of nuclear transcription factor, X-
box binding 1 (NFX1-91) repressor of telomerase (Gewin et al., 2004),
and possibly the proto-oncogene c-Myc (Gross-Mesilaty et al., 1998;
Veldman et al., 2003) and the O6-methylguanine-DNA methyltrans-
ferase (MGMT) (Srivenugopal and Ali-Osman, 2002), may bind to E6
only in the presence of E6-AP, so the E6I128T mutation probably affects
the binding of these proteins indirectly. Potentially, the interaction of
E6 with a variety of α-helical partners and with proteins that bind
only to the E6/E6-AP complex likely contributes to some aspects of its
ability to synergize with E7 in HNSCC, although based on our data,
other binding partners also play critical roles in this synergy.The interaction of HPV-16 E6 with multiple binding partners likely plays
a role in its ability to synergize with E7 in the head and neck
HPV-16 interacts with over two dozen intracellular proteins
(reviewed in (Tungteakkhun and Duerksen-Hughes, 2008)), and
many of them do not bind to E6 through any identiﬁed or well-
characterized motifs. It is possible that the interaction of E6 with
binding partners outside of theα-helical and PDZ-domain families are
important to head and neck tumorigenesis. The interaction of E6 with
Bak (Thomas and Banks, 1999), Fas-associated death domain protein
(FADD) (Filippova et al., 2004), procaspase-8 (Filippova et al., 2007),
and tumor necrosis factor receptor 1 (TNF R1) (Filippova et al., 2002),
all of which play a role in apoptosis, are some of the most obvious
candidates, although the binding of E6 to several other proteins
involved in genomic stability, epithelial differentiation, and transcrip-
tional regulation also probably contributes to its oncogenicity in the
head and neck. Until detailed mutational analysis of E6 is completed
and the regions of the oncoprotein that are important to binding to
individual intracellular proteins are identiﬁed, dissecting the speciﬁc
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remain difﬁcult, if not impossible.
In addition, it remains possible that eliminating the interaction of
E6 with both the α-helical and PDZ-domain families simultaneously
would result in a more dramatic effect than what we observed when
the interactionwith either family was abolished individually (Tables 1
and 2; Fig. 1). Perhaps the two families of binding partners play
overlapping roles in the head and neck, or maybe there is some
functional compensation between the α-helical and PDZ-domain
partners of E6 when only one of the two families is inactivated by the
viral oncoprotein. Interfering with the interaction of E6 with both
families simultaneously, perhaps by using an E6I128T/Δ146–151 double-
mutant, would permit an initial investigation of these possibilities,
although one important consideration would be whether mutating
more than one region of E6 would affect the structure of the
oncoprotein in a way that renders it functionally deﬁcient in
unexpected manners.
Materials and methods
Transgenic Mice
K14E6 (Song et al., 1999), K14E6I128T (Nguyen et al., 2002),
K14E6Δ146–151 (Nguyen et al., 2003a), and K14E7 (Herber et al.,
1996) transgenic mice have been described previously. All mice were
maintained on the FVB/n inbred genetic background, and all mice
were housed in the McArdle Laboratory Animal Care Unit, approved
by the Association for Assessment of Laboratory Animal Care, at the
University of Wisconsin Medical School. All protocols for animal work
were approved by the University of Wisconsin Medical School
Institutional Animal Care and Use Committee.
Irradiation studies
Groups of three 12- to 14-week-old mice of each genotype were or
were not exposed to 12 Gy radiation from a 137Cs source. 23 h post
exposure, mice were injected intraperitoneally with BrdU (300 μl of a
12.5 mg/ml solution). 1 h later mice were sacriﬁced, tongue and
esophagus formallin ﬁxed, parafﬁn embedded, and sectioned. Histo-
logical sections were deparafﬁnized in Xylenes, rehydrated in a series
of alcohols, boiled in 10 mM citrate buffer for 17 min to unmask
antigens, blocked in 10% horse serum in PBS for 1 h, then incubated
overnight at 4 °C with primary antibody speciﬁc for BrdU (Ab-2;
Calbiochem, San Diego, CA) diluted1:100 in block. A universally
biotinylated secondary antibody was applied for 30 minutes (Vectas-
tain universal secondary), washed in PBS, and incubated in ABC
(Vectastain, Vector labs, Burlingame, CA) reagent for 30 minutes.
Sections were developed with DAB reagent for appropriate time,
counterstained with hematoxylin, dehydrated in a series of alcohols
and cover slipped. The percentage of BrdU-positive cells was counted
in the tongue and esophagus epithelia of each mouse (ten 400×
microscope frames per mouse).
Treatment with 4-NQO
Six- to 8-week-old mice were treated for 8 weeks with 10 μg/mL
4-NQO (Sigma-Aldrich Corporation, St. Louis, MO) in their drinking
water, diluted from a stock solution of 0.2% 4-NQO (w/v) in propylene
glycol that was protected from light and stored at 4 °C. The mice then
were returned to a normal supply of water for an additional 16 weeks.
Harvest and analysis of tongues, esophagi, and overt tumors of the head
and neck
After completion of the treatment regimenwith 4-NQO,mice were
sacriﬁced. At the time of sacriﬁce, overt tumors in the oral cavity andesophagus were scored, measured across their largest dimension with
a ruler, and harvested; once the overt tumors were harvested, the
entire remaining tongue and esophagus also were harvested. Speci-
mens were ﬁxed overnight at 4 °C in 10% buffered formalin (v/v) and
then embedded in parafﬁn. Embedded tumors were cut into 5-μm-
thick sections, and 3 to 10 sections per tumor then were stained with
hematoxylin and eosin (H&E) and scored as papillomas or carcinomas.
Carcinomas were graded from I to IV based on morphology and the
degree of keratinization. For statistical comparisons of the severity of
disease between genotypes, mice were given a numerical value based
on the assigned grade of tumors. The values assigned were: 0 for no
overt tumors, 1 for papilloma, 2 for grade I carcinoma, 3 for grade II
carcinoma, 4 for grade III carcinoma, and 5 for grade IV carcinoma.
Statistical analyses
Speciﬁc comparisons done and statistical tests used are cited
within the text and in the captions of ﬁgures and tables.
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